Disposition of 5443 shares by Joseph Lyon of Corcept Therapeutics at 26.0011 subject to Rule 16b-3
CORT Stock | USD 27.83 0.17 0.61% |
Slightly above 52% of Corcept Therapeutics' private investors are presently thinking to get in. The analysis of overall sentiment of trading Corcept Therapeutics Incorporated stock suggests that some investors are interested at this time. Corcept Therapeutics' investor sentiment overview provides quick insight into current market opportunities from investing in Corcept Therapeutics Incorporated. The current market sentiment, together with Corcept Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Corcept Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Corcept Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Corcept daily returns and investor perception about the current price of Corcept Therapeutics Incorporated as well as its diversification or hedging effects on your existing portfolios.
Corcept |
Filed transaction by Corcept Therapeutics Incorporated Officer: See Remarks. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Cash Flow Correlation
Corcept Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Corcept Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Corcept Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Corcept Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Corcept Therapeutics Historical Investor Sentiment
Investor biases related to Corcept Therapeutics' public news can be used to forecast risks associated with an investment in Corcept. The trend in average sentiment can be used to explain how an investor holding Corcept can time the market purely based on public headlines and social activities around Corcept Therapeutics Incorporated. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Corcept Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Corcept Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Corcept Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Corcept Therapeutics.
Corcept Therapeutics Maximum Pain Price across 2024-05-17 Option Contracts
Corcept Therapeutics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Corcept Therapeutics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Corcept Therapeutics' options.
Corcept Therapeutics Fundamental Analysis
We analyze Corcept Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Corcept Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Corcept Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Liabilities
Current Liabilities Comparative Analysis
Corcept Therapeutics is currently under evaluation in current liabilities category among related companies. Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Corcept Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Corcept Therapeutics stock to make a market-neutral strategy. Peer analysis of Corcept Therapeutics could also be used in its relative valuation, which is a method of valuing Corcept Therapeutics by comparing valuation metrics with similar companies.
Peers
Corcept Therapeutics Related Equities
MGTX | MeiraGTx Holdings | 5.74 | ||||
HALO | Halozyme Therapeutics | 4.56 | ||||
NXTC | NextCure | 4.40 | ||||
DYN | Dyne TherapeuticsInc | 4.33 | ||||
AGIO | Agios Pharm | 3.05 | ||||
ERAS | Erasca | 1.61 | ||||
IDYA | Ideaya Biosciences | 1.53 | ||||
EWTX | Edgewise Therapeutics | 1.38 | ||||
ANAB | AnaptysBio | 1.35 | ||||
RARE | Ultragenyx | 0.37 | ||||
MLYS | Mineralys Therapeutics | 0.08 | ||||
MACK | Merrimack Pharmaceuticals | 0.07 | ||||
INSM | Insmed | 0.04 | ||||
CERE | Cerevel Therapeutics | 0.05 | ||||
CYTK | Cytokinetics | 0.26 | ||||
GLUE | Monte Rosa | 0.76 | ||||
SNSE | Sensei Biotherapeutics | 1.32 | ||||
NUVB | Nuvation Bio | 2.08 | ||||
KROS | Keros TherapeuticsInc | 2.57 |
Check out Corcept Therapeutics Hype Analysis, Corcept Therapeutics Correlation and Corcept Therapeutics Performance. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Corcept Stock analysis
When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |
Is Corcept Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corcept Therapeutics. If investors know Corcept will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corcept Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.786 | Earnings Share 1.05 | Revenue Per Share 5.118 | Quarterly Revenue Growth 0.39 | Return On Assets 0.1197 |
The market value of Corcept Therapeutics is measured differently than its book value, which is the value of Corcept that is recorded on the company's balance sheet. Investors also form their own opinion of Corcept Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Corcept Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corcept Therapeutics' market value can be influenced by many factors that don't directly affect Corcept Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corcept Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corcept Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corcept Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.